Breaking Finance News

Seattle Genetics (NDAQ:SGEN) stock price target bumped up to $69.00, released a research note earlier today by RBC Capital Markets

RBC Capital Markets upped the target price of Seattle Genetics (NDAQ:SGEN) to $69.00 indicating a possible upside of 0.20%.

Yesterday Seattle Genetics (NDAQ:SGEN) traded 1.91% higher at $57.42. Seattle Genetics’s 50-day average is $57.04 and its two hundred day average is $57.64. With the last stock price close down 8.19% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Volume of trade was down over the average, with 302,074 shares of SGEN changing hands under the typical 1,030,190

Performance Chart

Seattle Genetics (NDAQ:SGEN)

With a total market value of $0, Seattle Genetics has with a one year low of $45.31 and a one year high of $75.36 .

More About Seattle Genetics (NDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *